Today, the registered shares of Idorsia Ltd (“Idorsia”) were listed and traded for the first time under the “International Reporting Standard” of SIX Swiss Exchange. The opening price was CHF 10.00. This corresponds to a market capitalization of CHF 1.073 billion.
Idorsia was incorporated on 2 March 2017 as a wholly-owned subsidiary of Actelion Ltd (“Actelion”). At the General Meeting of Actelion held on 5 April 2017, the shareholders approved the demerger distribution, as a result of which all Actelion shareholders will receive one Idorsia share per each Actelion share held. The demerger distribution and the listing of Idorsia shares take place within the context of the public tender offer by Janssen Holding GmbH, a subsidiary of Johnson & Johnson, for all publicly held registered shares of Actelion.
As of today, the issued share capital of Idorsia comprises of 107,330,210 registered shares with a nominal value of CHF 0.05. A public offering of the company’s shares has not taken place.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet.
